Image may be NSFW.
Clik here to view.
Acorda Therapeutics (NSDQ:ACOR) said this week that the FDA approved its Inbrija device for the intermittent treatment of “off” episodes in people with Parkinson’s disease.
The self-administered, inhaled therapy is designed for people experiencing a re-emergence of Parkinson’s symptoms. These “off” episodes are caused by low levels of dopamine between doses of the standard oral Parkinson’s therapy, carbidopa/levodopa, according to Acorda.
Get the full story at our sister site, Drug Delivery Business News.
The post Acorda wins FDA nod for inhaled Parkinson’s therapy appeared first on MassDevice.
